Breaking News Instant updates and real-time market news.

ADMS

Adamas Pharmaceuticals

$5.87

-0.01 (-0.17%)

, CAH

Cardinal Health

$45.66

-0.09 (-0.20%)

04:55
06/27/19
06/27
04:55
06/27/19
04:55

Drug Information Association to hold a meeting

2019 Global Annual Meeting of DIA is being held in San Diego, CA on June 23-27.

ADMS

Adamas Pharmaceuticals

$5.87

-0.01 (-0.17%)

CAH

Cardinal Health

$45.66

-0.09 (-0.20%)

CRM

Salesforce

$148.98

-0.38 (-0.25%)

DTRK

DATATRAK International

$0.00

(0.00%)

ESRX

Express Scripts

$0.00

(0.00%)

HURN

Huron

$49.75

-1.24 (-2.43%)

INSM

Insmed

$24.54

-1.1 (-4.29%)

IQV

Iqvia

$155.64

1.51 (0.98%)

JAZZ

Jazz Pharmaceuticals

$136.82

0.3 (0.22%)

LIOX

Lionbridge

$0.00

(0.00%)

MASI

Masimo

$141.87

-2.64 (-1.83%)

MEDP

Medpace

$61.83

-0.33 (-0.53%)

MSFT

Microsoft

$133.91

0.48 (0.36%)

PRAH

PRA Health

$95.00

-0.92 (-0.96%)

SENS

Senseonics

$1.86

-0.07 (-3.63%)

VEEV

Veeva

$156.16

-0.98 (-0.62%)

WX

WuXi PharmaTech

$0.00

(0.00%)

  • 27

    Jun

  • 28

    Jun

  • 02

    Jul

  • 09

    Jul

  • 10

    Jul

  • 17

    Jul

  • 30

    Jul

  • 06

    Aug

  • 15

    Aug

  • 09

    Sep

  • 12

    Sep

ADMS Adamas Pharmaceuticals
$5.87

-0.01 (-0.17%)

03/05/19
COWN
03/05/19
DOWNGRADE
Target $15
COWN
Market Perform
Cowen downgrades Adamas to Market Perform, halves target to $15
Cowen analyst Ken Cacciatore downgraded Adamas Pharmaceuticals to Market Perform from Outperform and lowered his price target for the shares to $15 from $30. Last night's disclosure that Gocovri's prescription trajectory is flattening and that growth for the next several quarters is expected to be erratic is "concerning this early in the launch," Cacciatore tells investors in a post-earnings research note. Management's own caution "now raises many questions that we simply can't answer," says the analyst.
03/05/19
03/05/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Uniti Group (UNIT) downgraded to Underperform from Market Perform at Wells Fargo with analyst Jennifer Fritzsche saying the company released an 8K which indicated a significant cut in the dividend. 2. Adamas Pharmaceuticals (ADMS) downgraded to Underperform from Neutral at Mizuho, to Market Perform from Outperform at Cowen, and to Hold from Buy at Needham. 3. SQM (SQM) downgraded to Neutral from Buy at Citi with analyst Andrew McCarthy saying he continues to like the long-term lithium demand story but does not expect share price outperformance over the next 12 months. 4. Orange SA (ORAN) downgraded to Equal Weight from Overweight at Barclays with analyst Mathieu Robilliard saying an "irrational level of promotions" in 2018 continue to weigh on French telecoms. 5. Inter Parfums (IPAR) downgraded to Neutral from Buy at DA Davidson with analyst Linda Bolton Weiser citing valuation. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
03/05/19
NEED
03/05/19
DOWNGRADE
NEED
Hold
Adamas Pharmaceuticals downgraded to Hold from Buy at Needham
Needham analyst Serge Belanger downgraded Adamas Pharmaceuticals to Hold after the management pulled its forecast for 2% Rx market share for the company's Gocovri given its reported weakness in Q4 and expectations for Q1. The analyst states that the seasonal factors related to early-year insurance plan resets and pharma industry changes, along with the timing of Osmolex launch, have further disrupted Gocovri performance. Belanger notes that the lack of visibility on the product takes his rating to neutral until he sees some signs that the Gocovri launch ramp can re-accelerate.
05/28/19
HCWC
05/28/19
NO CHANGE
Target $30
HCWC
Buy
Adamas Pharmaceuticals price target lowered to $30 from $40 at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju lowered his price target for Adamas Pharmaceuticals to $30 from $40 while reiterating a Buy rating on the shares. The stock currently trades at a sub-$100M enterprise value, which is "overkill" and reflects very low expectations for Gocovri, let alone the ADS-5102 program, Selvaraju tells investors in a research note.
CAH Cardinal Health
$45.66

-0.09 (-0.20%)

04/17/19
GUGG
04/17/19
INITIATION
Target $51
GUGG
Neutral
Cardinal Health initiated with a Neutral at Guggenheim
Guggenheim analyst Glen Santangelo initiated Cardinal Health with a Neutral rating and a price target of $51. The analyst says that while the company is "operating in a difficult environment in both its Pharmaceutical and Medical segments", it is showing signs of stabilization operationally. Santangelo also warns however that Cardinal Health's upside potential will be limited as long as investors are focused on the "potential for unfavorable regulatory change and the implications of the ongoing opioid litigation."
04/17/19
GUGG
04/17/19
INITIATION
Target $51
GUGG
Neutral
Cardinal Health initiated with a Neutral at Guggenheim
Guggenheim initiated Cardinal Health with a Neutral rating and $51 price target.
04/17/19
GUGG
04/17/19
INITIATION
Target $72
GUGG
Neutral
Cardinal Health initiated with a Neutral at Guggenheim
Guggenheim initiated Cardinal Health with a Neutral and $72 price target.
04/03/19
MSCO
04/03/19
NO CHANGE
MSCO
Morgan Stanley says Walgreens' reimbursement pressure points to distributor risk
Morgan Stanley analyst Ricky Goldwasser said the guidance cut made by Walgreens Boots Alliance (WBA) is due to the same "perfect storm of industry headwinds" addressed by CVS Health (CVS) earlier in the year, including increased reimbursement pressure, lower generic deflation, lower brand inflation and declining comparable sales in the front-end of the store. Though Walgreens management suggested reimbursement headwinds should normalize in fiscal 2020, Goldwasser said he could see more downside from continued reimbursement headwinds and structural changes if new rebate rule comes into play. He also views pharmacy reimbursement pressure as a leading indicator suggesting risk to distributors' sell side margins and earnings, including for AmerisourceBergen (ABC), which Goldwasser notes is part of the WBAD purchasing consortium. Other drug distributors include McKesson (MCK) and Cardinal Health (CAH).
CRM Salesforce
$148.98

-0.38 (-0.25%)

06/21/19
WEDB
06/21/19
DOWNGRADE
Target $176
WEDB
Neutral
Tableau downgraded to Neutral, while price target raised to $176 at Wedbush
Wedbush analyst Steve Koening downgraded Tableau (DATA) to Neutral from Outperform to reflect the pending takeover by Salesforce (CRM). At the same time, the analyst raised his price target to $176 from $153, saying he expects Salesforce to handle the integration "carefully," and that the combination will likely see significant revenue synergy in 12-24 months, as Salesforce is able to leverage its visibility to major digital transformation initiatives to accelerate Tableau's business.
06/19/19
UBSW
06/19/19
DOWNGRADE
Target $166
UBSW
Neutral
Tableau downgraded to Neutral from Buy at UBS
UBS analyst Jennifer Swanson Lowe downgraded Tableau Software (DATA) to Neutral from Buy while raising her price target for the shares to $166 from $159 to reflect the takeover by Salesforce (CRM).
06/13/19
RBCM
06/13/19
NO CHANGE
Target $181
RBCM
Outperform
Salesforce price target lowered to $181 from $183 at RBC Capital
RBC Capital analyst Matthew Hedberg lowered his price target on Salesforce (CRM) to $181 after its all-stock acquisition of Tableau (DATA). The analyst notes that the $15.7B price tag and "overlap with an existing analytics footprint" gives him some "pause" in endorsing the deal, but he is prepared to give Salesforce management the benefit of the doubt given the company's strong M&A track record. The analyst lowers his FY20 and FY21 EPS view by 20c and 26c to $2.69 and $3.27 respectively to reflect the deal's dilution, but keeps his Outperform rating on Salesforce shares.
06/12/19
SBSH
06/12/19
DOWNGRADE
SBSH
Neutral
Citi sees competitive bidding process for Tableau as unlikely
Citi analyst Tyler Radke downgraded Tableau Software (DATA) to Neutral from Buy with a $178 price target to reflect the pending takeover by Salesforce (CRM). The analyst continues to see a competitive bidding process as unlikely. Radke continues to favor Alteryx (AYX) as his top pick given the company's combination of "strong top-line growth paired with near best-in-class unit economics and profitability." Further, he believes Alteryx's market opportunity may be underestimated. Talend (TLND) moves to the analyst's second pick.
DTRK DATATRAK International
$0.00

(0.00%)

ESRX Express Scripts
$0.00

(0.00%)

12/18/18
RBCM
12/18/18
NO CHANGE
Target $34
RBCM
Outperform
AMD addition to Nasdaq-100 a 'small near-term positive', says RBC Capital
RBC Capital analyst Mitch Steves notes the addition of AMD (AMD) to the Nasdaq-100 index announced late on Friday, which also contained the inclusion of lululemon (LULU), NetApp (NTAP), United Continental Holdings (UAL), VeriSign (VRSN) and Willis Towers Watson (WLTW) and the subtraction of Express Scripts Holding (ESRX), Hologic (HOLX), Qurate Retail (QRTEA), Shire (SHPG), Seagate Technology (STX) and Vodafone Plc (VOD). The analyst believes that the change - which will become effective before the market open on December 24th - could act as a "small near-term positive" for AMD shares, even though it does not change its fundamentals. Longer term, the analyst keeps his Outperform rating and $34 price target on AMD, but warns that the company is faced with a crypto currency downdraft in the Gaming segment and that he is also cautious on the hyperscale spending trends next year which he estimates in the low single digits. Steves adds that the notable investor debate is also taking place around the AMD server average selling prices, which he sees coming in around $5,400 - the higher end of the more bullish forecasts of $5K-$6K vs. the bears' estimate around $4K.
01/16/19
MSCO
01/16/19
NO CHANGE
MSCO
Morgan Stanley says UnitedHealth, Walgreens could benefit from CVS-Walmart fight
After CVS Health (CVS) announced Walmart (WMT) will leave Caremark's commercial and Managed Medicaid retail pharmacy networks at the end of April 2019, analysts at Morgan Stanley discussed the potential impact of the fight to both companies and to competitors. Analyst Ricky Goldwasser said the dispute "brings back memories" of the Express Scripts (ESRX) and Walgreens (WBA) breakup in 2011, but unlike in that case it is only the early days of the 2019/2020 selling season, not after the selling season concluded. Walmart's plans to leave should have a limited impact on CVS' FY19 EPS power, but adds uncertainty to PBM selling season if not resolved in the near-term, said Goldwasser. Morgan Stanley's Simeon Gutman said that if the dispute is not resolved, it could end up reducing Walmart's EBIT by about $260M in 2019, which he estimates could have a 7c, or 1.5%, impact on EPS. In terms of who may benefit if no resolution is reached, the team estimates both Walgreens and CVS retail could gain an incremental 25 bps of pharmacy share and that UnitedHealth's (UNH) Optum and Cigna (CI) could see a step up in PBM selling season win rates. However, given Walmart's relatively low share, they view the PBM share opportunity as "minimal."
01/03/19
WELS
01/03/19
NO CHANGE
Target $200
WELS
Market Perform
Cigna price target lowered to $200 from $221 at Wells Fargo
Wells Fargo analyst Peter Costa believes Anthem (ANTM) and Cigna (CI) may be spending much time in court fighting each other in 2019 and sees more risk for the latter than Anthem, since even if Cigna wins the first case it would have risk of losing the second where the sought damages against it are greater. Hence, it is possible that Cigna could agree to settle both cases for limited gains, he contends. Given the timing and Cigna's weakened balance sheet post the Express Scripts (ESRX) merger and plans to use Express Scripts' cash flow to reduce debt, Costa lowered his price target for Cigna to $200 from $221 and reiterated a Market Perform rating on the shares.
12/20/18
JPMS
12/20/18
NO CHANGE
JPMS
Overweight
JPMorgan calls Cigna top idea to own into its Healthcare Conference
JPMorgan analyst Gary Taylor says Cigna (CI) is his top short-term idea to own into the 2019 JPMorgan Healthcare Conference. The analyst anticipates Cigna at the conference will be prepared to provide "at least high-level combined-company proforma 2019 guidance." He sees a "valuation catalyst" in the closing of the Express Scripts (ESRX) deal and keeps an Overweight rating on Cigna with a $250 price target.
HURN Huron
$49.75

-1.24 (-2.43%)

08/01/18
08/01/18
UPGRADE
Target $52

Buy
Huron upgraded to Buy with $52 price target at Benchmark
As previously reported, Benchmark analyst Bill Sutherland upgraded Huron to Buy from Hold after all three of its segments produced better revenue trends in Q2. He believes this demonstrates the pay off from recent initiatives to reposition and views the company as well positioned given its focus on Healthcare and Higher Education, which Sutherland calls two sectors with expanding operating and financial challenges. He set a $52 price target on Huron shares.
02/27/19
RHCO
02/27/19
NO CHANGE
Target $60
RHCO
Buy
Huron price target raised to $60 from $55 at SunTrust
SunTrust analyst Tobey Sommer raised his price target on Huron to $60 and kept his Buy rating, saying the company's education segment should benefit from the struggles of the universities business model. The analyst sees a "long-term runway for growth in the number and scope of engagements for Huron Education" after the segment registered a 16% organic revenue growth in 2018.
08/28/18
BRRR
08/28/18
UPGRADE
Target $55
BRRR
Outperform
Huron upgraded to Outperform from Market Perform at Barrington
Barrington analyst Kevin Steinke upgraded Huron Consulting Group to Outperform with a price target of $55. The analyst believes the company's Healthcare segment is poised for a rebound with margins set to improve beyond 2018. Commentary about the Healthcare segment on Huron's Q2 conference call "changed meaningfully," as management expressed optimism in the sustainability of improved demand compared to its cautiousness in recent quarters, Steinke tells investors in a research note.
09/19/18
WBLR
09/19/18
NO CHANGE
WBLR
Outperform
Huron has 'hidden asset' with Shorelight Education, says William Blair
William Blair analyst Timothy McHugh believes Huron Consulting Group's investment in privately held Shorelight Education is an "overlooked" and "hidden" asset. Shorelight helps universities recruit and educate non-U.S. students, the analyst tells investors in a research note. He points out that the number of students enrolled worldwide in foreign countries increased annually at a 6% from 2000 to 2014, and is expected to grow at a 4%-5% rate through 2025. Huron carried the 20% ownership interest in Shorelight on its balance sheet at $47M last quarter, which is up from $35M most of last year, McHugh writes. The analyst believes the value of Huron's investment could be "meaningfully higher" if assuming $100M to $150M of revenue and a 3-7 times revenue multiple. McHugh keeps an Outperform rating on Huron Consulting Group.
INSM Insmed
$24.54

-1.1 (-4.29%)

04/09/19
HCWC
04/09/19
NO CHANGE
Target $52
HCWC
Buy
Insmed price target raised to $52 from $43 at H.C. Wainwright
H.C. Wainwright analyst Andrew Fein raised his price target for Insmed to $52 from $43 saying the company yesterday announced a positive update on the U.S. launch of Arikayce. The broadening of the prescriber base "is not short lived and can continue, as well as possibly be supplemented by label expansion into first line patients," Fein tells investors in a research note. He keeps a Buy rating on the shares.
03/26/19
STFL
03/26/19
NO CHANGE
Target $43
STFL
Buy
Pulmonologist call reinforces Stifel view of upside for Insmed
After hosting a conference call with two key opinion leader pulmonologists to discuss the rollout of Arikayce, Stifel analyst Adam Walsh said their feedback suggested the strong start for the drug was not the result of a "bolus" of patients awaiting approval and noted that both doctors said their new-patient starts remain steady. While it "remains early days in the launch," the call with the doctors reinforced his belief that Insmed's Arikayce guidance is likely conservative, Walsh tells investors. He keeps a Buy rating and $43 price target on Insmed shares.
02/15/19
JMPS
02/15/19
UPGRADE
Target $40
JMPS
Outperform
Insmed upgraded to Outperform following Arikayce survey at JMP Securities
As previously reported, JMP Securities analyst Liisa Bayko upgraded Insmed to Outperform from Market Perform, stating that her survey of "early adopters" of Arikayce shows a high rate of utilization with a favorable early experience that is encouraging more usage. This suggests Arikayce will beat 2019 consensus, contends Bayko, who raised her 2019 Arikayce revenue estimates. She set a $40 price target on Insmed shares.
03/08/19
ADAM
03/08/19
NO CHANGE
Target $44
ADAM
Buy
Insmed price target raised to $44 from $32 at Canaccord
Canaccord analyst Dewey Steadman raised his price target on Insmed to $44 from $32 following Q4 results. The analyst was impressed with the Arikayce uptake to-date and he thinks its initial guidance leaves room for a beat once Medicare dynamics are fully understood. He also sees continued growth in the Arikayce franchise and its pulmonary pipeline provides additional upside optionality. Steadman reiterated his Buy rating on Insmed shares.
IQV Iqvia
$155.64

1.51 (0.98%)

06/19/19
FBCO
06/19/19
NO CHANGE
Target $165
FBCO
Outperform
Iqvia price target raised to $165 from $159 at Credit Suisse
Credit Suisse analyst Erin Wilson Wright raised her price target for Iqvia to $165 from $159 after the company unveiled new three-year medium-term guidance, calling for accelerating revenue growth, reflecting building momentum across both Technology and Research. The analyst reiterates an Outperform rating on the shares.
06/19/19
MSCO
06/19/19
NO CHANGE
Target $170
MSCO
Overweight
Iqvia price target raised to $170 from $156 at Morgan Stanley
Morgan Stanley analyst Ricky Goldwasser raised his price target on Iqvia shares to $170 from $156 following the company's analyst day, which he called "an impressive showcase of capabilities" that also featured the company introducing 2022 targets that topped his expectations. The guidance implies accelerated organic growth across all segments, noted Goldwasser, who thinks that datapoints from Real World Insights validate the company's data-centric strategy and sees the company's CORE-powered solutions having the potential to be "a game changer for the industry." He keeps an Overweight rating on Iqvia shares.
06/21/19
MZHO
06/21/19
UPGRADE
Target $175
MZHO
Buy
Iqvia upgraded to Buy from Neutral at Mizuho
Mizuho analyst Ann Hynes upgraded Iqvia Holdings to Buy from Neutral and raised her price target for the shares to $175 from $150. Iqvia's investor day made it clear that its "not just differentiated from its peers, the company is actually light years ahead of its competitors," Hynes tells investors in a research note. The analyst thinks Iqvia's competitive advantage increases its growth potential over the long-term. She feels the company is in the "early innings" of market share gains and that it should be valued as a "tech disruptor."
06/21/19
06/21/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. LabCorp (LH) upgraded to Buy from Hold at Deutsche Bank with analyst Dan Leonard saying he has an "increasingly constructive" view on the Covance contract research business, and believes risks in Diagnostics "now skew to the upside." 2. SeaWorld (SEAS) upgraded to Buy from Neutral at Goldman Sachs with analyst Christopher Prykull saying the company's ongoing revenue optimization efforts are still being underappreciated by the market. 3. Crocs (CROX) upgraded to Outperform from Neutral at Baird. 4. Phillips 66 (PSX) upgraded to Buy from Neutral at Citi. 5. Iqvia (IQV) upgraded to Buy from Neutral at Mizuho with analyst Ann Hynes saying Iqvia's investor day made it clear that its "not just differentiated from its peers, the company is actually light years ahead of its competitors." This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
JAZZ Jazz Pharmaceuticals
$136.82

0.3 (0.22%)

05/28/19
PIPR
05/28/19
NO CHANGE
Target $202
PIPR
Overweight
Jazz Pharmaceuticals risk/reward attractive, says Piper Jaffray
After traveling with management, Piper Jaffray analyst David Amsellem reiterates an Overweight rating on Jazz Pharmaceuticals with a $202 price target. The analyst continues to believe that visibility into "durable longer-term" cash flows for Jazz is high, given what in he views will be significant contribution from JZP-258 and Sunosi. He sees an attractive risk/reward profile at current share levels.
03/27/19
MZHO
03/27/19
NO CHANGE
Target $147
MZHO
Buy
Jazz Pharmaceuticals price target raised to $147 from $137 at Mizuho
Mizuho analyst Irina Koffler raised her price target for Jazz Pharmaceuticals to $147 from $137 to reflect the recent approval of Sunosi and last night's positive data in the Phase III trial of JZP-258. However, both of these events were largely expected, Koffler tells investors in a research note. She reiterates a Neutral rating on Jazz Pharmaceuticals.
06/17/19
WELS
06/17/19
NO CHANGE
WELS
Jazz Schedule IV medicine designation a positive outcome, says Wells Fargo
Jazz Pharmaceuticals this morning announced that the U.S. Drug Enforcement Agency has given Sunosi, formerly known as JZP110, a Schedule IV medicine designation, Wells Fargo analyst David Maris tells investors in a research note. The analyst, who points out Provigil is also a Schedule IV drug, believes this outcome is a positive for Jazz and Sunosi. Maris models Sunosi sales of $12M in 2019 and approximately $180M in sales by 2021. He keeps an Outperform rating on shares of Jazz Pharmaceuticals.
06/11/19
LEHM
06/11/19
INITIATION
Target $164
LEHM
Overweight
Jazz Pharmaceuticals initiated with an Overweight at Barclays
Barclays analyst Balaji Prasad started Jazz Pharmaceuticals with an Overweight rating and $164 price target. The analyst launched coverage of 20 U.S. Specialty Pharmaceuticals with a Neutral industry view. He placed importance on cash flows and companies' ability to manage leverage and improve balance sheets.
LIOX Lionbridge
$0.00

(0.00%)

MASI Masimo
$141.87

-2.64 (-1.83%)

04/16/19
BTIG
04/16/19
DOWNGRADE
BTIG
Neutral
Masimo downgraded to Neutral from Buy at BTIG
BTIG analyst Sean Lavin downgraded Masimo (MASI) to Neutral mainly on valuation concerns, stating that while nothing has changed in his positive expectations for the company's performance, the stock may be "running out of steam". The analyst believes that Masimo should continue "taking market share, post strong revenue growth supported by multiple drivers, and enjoy adoption uplift through the Philips (PHG) co-marketing deal", but also sees the valuation on the stock reflecting "a good deal of the good news".
05/17/19
STFL
05/17/19
NO CHANGE
Target $160
STFL
Buy
Masimo price target raised to $160 from $150 at Stifel
Stifel analyst Rick Wise raised his price target on Masimo shares to $160 from $150 following the company's analyst day meeting, stating that the event reinforced his view of Masimo as a consistent high-single-to low-double digit top-line grower "with an equally impressive margin expansion opportunity." He also left the event with an even greater appreciation for the depth and breadth of Masimo's suite of solutions and its pipeline, said Wise, who keeps a Buy rating on the stock.
05/17/19
PIPR
05/17/19
NO CHANGE
Target $160
PIPR
Overweight
Masimo price target raised to $160 from $148 at Piper Jaffray
Piper Jaffray analyst William Quirk raised his price target for Masimo to $160 from $148 citing greater visibility into the company's pipeline opportunities following its analyst day. Masimo is widening its technology advantage over competitors, and also opening "several attractive" multi-billion dollar markets, Quirk tells investors in a research note. Masimo introduced Opioid SafetyNet, a home monitoring too, as well as a noninvasive PaO2 and malaria test, the analyst points out. He believes Masimo shares can continue working higher.
05/07/19
PIPR
05/07/19
NO CHANGE
Target $148
PIPR
Overweight
Masimo price target raised to $148 from $140 at Piper Jaffray
Piper Jaffray analyst William Quirk raised his price target for Masimo to $148 from $140 following the company's better than expected Q1 results and increased outlook. The analyst now has higher confidence in the company's prospects heading into the analyst day and he reiterates an Overweight rating on the shares.
MEDP Medpace
$61.83

-0.33 (-0.53%)

04/02/19
WOLF
04/02/19
INITIATION
Target $64
WOLF
Outperform
Medpace linitiated with an Outperform at Wolfe Research
Wolfe Research initiated Medpace with an Outperform and $64 price target citing valuation, an increasing net cash position, and likely buybacks.
09/17/18
RHCO
09/17/18
INITIATION
Target $63
RHCO
Hold
Medpace initiated with a Hold at SunTrust
SunTrust analyst Sandy Draper initiated Medpace at Hold with a price target of $63, saying the company's exposure to a smaller market segment and "full service only business model" positions it for "above average growth and industry high margins". The analyst adds that while this commands a "modest premium" valuation, the secret on the company's prospects "is out", as the 23-times next-twelve-month valuation multiple for Medpace is at the top of its historical range.
10/31/18
RHCO
10/31/18
UPGRADE
RHCO
Buy
Medpace upgraded to Buy from Hold at SunTrust
10/31/18
RHCO
10/31/18
UPGRADE
Target $63
RHCO
Buy
Medpace upgraded to Buy at SunTrust on valuation
As reported earlier, SunTrust analyst Sandy Draper upgraded Medpace to Buy from Hold and kept his $63 price target, citing its more attractive valuation of 11% discount relative to clinical research organization group vs. 6% premium in his last review. The analyst notes that he remains positive on the company's "high exposure to small and medium biotech sponsors" and believes that its multiple is justified even after a "beat and raise" Q3 result.
MSFT Microsoft
$133.91

0.48 (0.36%)

06/20/19
STFL
06/20/19
NO CHANGE
Target $48
STFL
Hold
Stifel says 'not much to be excited about' at Oracle beyond valuation
Stifel analyst Brad Reback noted that Oracle (ORCL) reported Q4 revenue and EPS that beat guidance along with its highest operating margin in five years, but he is still cautious given decelerating growth in the apps business, his view that Oracle continues to lose share in the database market and what he sees as a weak position in Infrastructure-as-a-Service. In a post-earnings research noted titled "Outside of valuation...Not much to be excited about," Reback noted that negatives in the company's Q4 report included decelerating share repurchases, a decreased net cash position and increasing FY20 capital expenditures that will weigh on free cash flow. The analyst, who also said that Microsoft's (MSFT) server-products and cloud-services are growing about eight times faster than Oracle's infrastructure business, keeps a Hold rating and $48 price target on Oracle shares.
06/25/19
JEFF
06/25/19
NO CHANGE
Target $90
JEFF
Underperform
Microsoft Azure likely never sees AWS-like margins, says Jefferies
Jefferies analyst John DiFucci said he continues to believes Microsoft (MSFT) shares are "materially overvalued," contending that evidence suggests that the widely-held assumption that Azure profit will come with scale, similar to how it did for Amazon Web Services (AMZN), is incorrect. Azure will likely never see margins similar to AWS at scale, argues DiFucci, who also thinks AWS long-term margins may be lower than most expect. The analyst, who admits that Microsoft "is one of the greatest software success stories in the short history of the sector," keeps an Underperform rating on the stock and raised his price target on the shares to $90 from $80. Microsoft shares closed Monday trading up 81c, or 0.6%, to $137.78.
06/26/19
WEDB
06/26/19
NO CHANGE
WEDB
Pentagon JEDI contract to be 'defining moment' for cloud arms race, says Wedbush
Wedbush analyst Daniel Ives believes a "defining moment" for the cloud arms race will be the announcement of the winner of the long-awaited Pentagon JEDI contract, which is worth roughly $10B over the next decade in this landmark deal representing the cloud "grand prize" for Amazon (AMZN) and Microsoft (MSFT). The analyst notes that the timing on the announcement of a winner could be late August/early September with the ongoing Oracle (ORCL) lawsuit a wild card that could push the timeline out further depending on the outcome. While AWS/Amazon have been in pole position to win this deal over the last year, Ives continues to hear from his Beltway contacts that Microsoft has made "steady and impressive progress" and significantly narrowed the gap over the last six months with the odds of a win looking more like a realistic possibility.
06/19/19
WEDB
06/19/19
NO CHANGE
WEDB
DOJ 'bark worse than the bite,' FAANG breakups not likely, says Wedbush
Wedbush analyst Daniel Ives notes that the noise is getting louder around regulation and antitrust concerns with FAANG names such as Amazon (AMZN), Facebook (FB), Google (GOOG), and Apple (AAPL), and while this is not a new issue per se, there is growing rhetoric around big tech's grip on e-commerce, digital advertising, the app ecosystem, social media, and search among other areas of the tech food chain. The analyst ultimately believes this is more noise versus the start of broader structural changes across the tech food chain and will likely result in business model tweaks and potential DOJ/FTC fines in a worst-case scenario rather than forced breakups of the underlying businesses. That said, Ives acknowledges that these potential DOJ probes could be an overhang on the stocks, but would encourage investors to focus on the fundamentals in the near-term as any probe would take many years to complete as witnessed first-hand with Microsoft (MSFT), which proved to be more noise than a structural jolt to its business model. Further, the analyst believes that Congress will investigate claims of anticompetitive behavior, but ultimately expects a "no harm, no foul" outcome on these FAANG names.
PRAH PRA Health
$95.00

-0.92 (-0.96%)

05/02/19
KEYB
05/02/19
DOWNGRADE
KEYB
Sector Weight
PRA Health downgraded to Sector Weight from Overweight at KeyBanc
04/02/19
WOLF
04/02/19
INITIATION
Target $112
WOLF
Peer Perform
PRA Health initiated with a Peer Perform at Wolfe Research
Wolfe Research started PRA Health with a Peer Perform rating and $112 price target, stating that the firm is cautious on softening gross bookings in the second half of 2018 and the revenue ramp and margin improvement imbedded in guidance for 2019.
05/03/19
KEYB
05/03/19
DOWNGRADE
KEYB
Sector Weight
PRA Health downgraded to Sector Weight from Overweight at KeyBanc
KeyBanc analyst Donald Hooker downgraded PRA Health to Sector Weight from Overweight and lowered his model estimates to bake-in additional caution with respect to the performanceof the Symphony Health business that was acquired in late 2017. Revenues declined y/y and management made a change in leadership with plans to make additional investments to grow the business, Hooker tells investors in a research note, adding that he is lowering his 2020E adjusted EBITDA to $582M with a base case valuation in line now with the broader biopharma outsourcing space.
06/03/19
BARD
06/03/19
NO CHANGE
Target $122
BARD
Outperform
PRA Health designated as a Fresh Pick at Baird
Baird analyst Eric Coldwell designated PRA Health as a Fresh Pick as he believes the recent selloff in the shares is overdone. The analyst said the price is now right to assume risks and look through recent concerns. He said the premium story is now trading at a discount, and he sees the shares capable of rallying back toward $100 in the near term. Coldwell reiterated his Outperform rating and $122 price target on PRA Health.
SENS Senseonics
$1.86

-0.07 (-3.63%)

06/06/19
PIPR
06/06/19
NO CHANGE
PIPR
Senseonics receives FDA claim for Eversense CGM system, says Piper Jaffray
Piper Jaffray analyst JP McKim maintained a Neutral rating and $2.70 price target on Senseonics, while noting that the company "received a non-adjunctive claim for their Eversense CGM system" from the FDA. The analyst said that the claim would allow Eversense "to be used in replacement for finger stick glucose measurements" and added that it "is a needed claim to begin the process to unlock the Medicare population and represents an important stage in their commercialization process."
11/27/18
UBSW
11/27/18
INITIATION
UBSW
Sell
Senseonics initiated with a Sell at UBS
UBS analyst Matthew Taylor initiated Senseonics with a Sell rating and $2 price target, calling the stock a Top Sell. Taylor said he sees risks to the downside given his view that "Eversense is a niche product and competition is improving."
02/04/19
PIPR
02/04/19
NO CHANGE
Target $2.7
PIPR
Neutral
Piper Jaffray uncertain of benefits from increased Roche access for Senseonics
Piper Jaffray analyst JP Kim kept his Neutral rating and $2.70 price target on Senseonics (SENS) after the company announced an extension of agreement with Roche (RHHBY). The analyst notes that the management is likely willing to trade off the near term price gains for long term volume gain through this deal, but adds that a reset of consensus estimates for sales that would lead to Senseonics becoming a "beat and raise story" is uncertain.
01/29/19
PIPR
01/29/19
INITIATION
Target $2.7
PIPR
Neutral
Senseonics initiated with a Neutral at Piper Jaffray
Piper Jaffray analyst JP McKim started Senseonics with a Neutral rating and $2.70 price target. The analyst believes the stock's risk/reward remains balanced over the next 12 months given the "hand to hand combat of reimbursement coverage and at its current 90 day configuration in the U.S."
VEEV Veeva
$156.16

-0.98 (-0.62%)

05/30/19
DADA
05/30/19
NO CHANGE
Target $165
DADA
Buy
Veeva price target raised to $165 from $160 at DA Davidson
DA Davidson analyst Rishi Jaluria raised his price target on Veeva to $165 and kept his Buy rating after its "strong" beat-and-raise Q1 results that showed accelerating subscription growth and a record high operating margin. The analyst says the latest quarter further supports his thesis that Veeva can become a multi-billion dollar SaaS company after it signed its first top 20 CDMS customer enterprise deal, saw early adopters for its Vault Safety product, and began a Vault Claims project with a top 20 CPG customer. Jaluria expects the company to cross a $1B run-rate in Q2.
05/30/19
ADAM
05/30/19
NO CHANGE
Target $135
ADAM
Buy
Veeva price target raised to $135 from $115 at Canaccord
Canaccord analyst David Hynes raised his price target on Veeva to $135 from $115 following Q1 results. The analyst cited the signing of a record of new customers, its breadth of products, and he believes there is a long runway ahead for the company. Hynes reiterated his Buy rating on Veeva shares.
06/07/19
GSCO
06/07/19
INITIATION
Target $151
GSCO
Neutral
Veeva initiated with a Neutral at Goldman Sachs
Goldman Sachs analyst Christopher Merwin started Veeva Systems with a Neutral rating and $151 price target.
05/30/19
RHCO
05/30/19
NO CHANGE
Target $150
RHCO
Buy
Veeva price target raised to $150 from $140 at SunTrust
SunTrust analyst Sandy Draper raised his price target on Veeva to $150 and kept his Buy rating after its Q1 results, citing the company's "record high" new Vault clients on-boarded in the quarter as it tracked to surpass Commercial Solutions business. The analyst also cites Veeva's 27% subscription revenue growth in Q1 - the fastest in 5 quarters - along with its 26% increase in billings. Draper further contends that while Veeva's legacy products are still doing well, its new products like Vault CDMS saw a notable top 20 Pharma commitment with a company-wide-rollout.
WX WuXi PharmaTech
$0.00

(0.00%)

TODAY'S FREE FLY STORIES

CHEOY

Cochlear

$0.00

(0.00%)

05:20
07/17/19
07/17
05:20
07/17/19
05:20
Downgrade
Cochlear rating change  »

Cochlear downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BURBY

Burberry

$0.00

(0.00%)

05:18
07/17/19
07/17
05:18
07/17/19
05:18
Downgrade
Burberry rating change  »

Burberry downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPI

SPI Energy

$2.26

0.03 (1.35%)

05:17
07/17/19
07/17
05:17
07/17/19
05:17
Hot Stocks
SPI Energy appoints Anthony Chan as CFO »

SPI Energy announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LEA

Lear

$129.75

-5.33 (-3.95%)

05:15
07/17/19
07/17
05:15
07/17/19
05:15
Downgrade
Lear rating change  »

Lear downgraded to Sector…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

NUS

Nu Skin

$45.50

1.44 (3.27%)

05:14
07/17/19
07/17
05:14
07/17/19
05:14
Downgrade
Nu Skin rating change  »

Nu Skin downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Aug

CHAC

Chardan Healthcare

$9.81

(0.00%)

05:13
07/17/19
07/17
05:13
07/17/19
05:13
Hot Stocks
Chardan Healthcare announces merger agreement with BiomX »

Chardan Healthcare…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LEVI

Levi Strauss

$19.81

-0.3 (-1.49%)

, RL

Ralph Lauren

$115.16

2.555 (2.27%)

05:11
07/17/19
07/17
05:11
07/17/19
05:11
Downgrade
Levi Strauss downgraded to Sell from Neutral at Goldman Sachs »

Goldman Sachs analyst…

LEVI

Levi Strauss

$19.81

-0.3 (-1.49%)

RL

Ralph Lauren

$115.16

2.555 (2.27%)

PVH

PVH Corp.

$92.50

2.08 (2.30%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jul

  • 01

    Aug

  • 19

    Sep

  • 19

    Sep

CRZO

Carrizo Oil & Gas

$11.21

0.5 (4.67%)

05:11
07/17/19
07/17
05:11
07/17/19
05:11
Downgrade
Carrizo Oil & Gas rating change  »

Carrizo Oil & Gas…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RL

Ralph Lauren

$115.16

2.555 (2.27%)

05:08
07/17/19
07/17
05:08
07/17/19
05:08
Downgrade
Ralph Lauren rating change  »

Ralph Lauren downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jul

  • 01

    Aug

  • 19

    Sep

PVH

PVH Corp.

$92.50

2.08 (2.30%)

05:06
07/17/19
07/17
05:06
07/17/19
05:06
Downgrade
PVH Corp. rating change  »

PVH Corp. downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

PVH

PVH Corp.

$92.50

2.08 (2.30%)

05:06
07/17/19
07/17
05:06
07/17/19
05:06
Downgrade
PVH Corp. rating change  »

PVH Corp. downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

SHLX

Shell Midstream

$21.52

0.32 (1.51%)

05:02
07/17/19
07/17
05:02
07/17/19
05:02
Downgrade
Shell Midstream rating change  »

Shell Midstream…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HSY

Hershey

$140.43

2.02 (1.46%)

05:00
07/17/19
07/17
05:00
07/17/19
05:00
Upgrade
Hershey rating change  »

Hershey upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

SGEN

Seattle Genetics

$63.12

-0.87 (-1.36%)

04:55
07/17/19
07/17
04:55
07/17/19
04:55
Upgrade
Seattle Genetics rating change  »

Seattle Genetics upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

04:55
07/17/19
07/17
04:55
07/17/19
04:55
Conference/Events
Credit Suisse energy analysts to hold an analyst/industry conference call »

Analysts provide a 2Q…

KSHB

KushCo Holdings

$0.00

(0.00%)

04:55
07/17/19
07/17
04:55
07/17/19
04:55
Conference/Events
KushCo Holdings management to meet with Compass Point »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

TELL

Tellurian

$7.68

-0.1 (-1.29%)

04:55
07/17/19
07/17
04:55
07/17/19
04:55
Conference/Events
Tellurian management to meet with Seaport Global »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

DOVA

Dova Pharmaceuticals

$16.07

(0.00%)

04:55
07/17/19
07/17
04:55
07/17/19
04:55
Conference/Events
Dova Pharmaceuticals management to meet with Jefferies »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

  • 18

    Jul

CRD.B

Crawford & Company

$9.34

-0.13 (-1.37%)

04:55
07/17/19
07/17
04:55
07/17/19
04:55
Conference/Events
Crawford & Company management to meet with William Blair »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

04:55
07/17/19
07/17
04:55
07/17/19
04:55
General news
Breaking General news story  »

Week of 7/12 MBA Mortgage…

PANW

Palo Alto Networks

$219.83

0.41 (0.19%)

, FTNT

Fortinet

$84.79

-0.19 (-0.22%)

04:55
07/17/19
07/17
04:55
07/17/19
04:55
Conference/Events
FBN Securities Tech/Internet analyst to hold a group luncheon »

Analyst Seyrafi holds a…

PANW

Palo Alto Networks

$219.83

0.41 (0.19%)

FTNT

Fortinet

$84.79

-0.19 (-0.22%)

PFPT

Proofpoint

$126.33

0.61 (0.49%)

CHKP

Check Point

$116.24

-1.37 (-1.16%)

SAIL

SailPoint

$20.12

-0.27 (-1.32%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

  • 24

    Jul

  • 25

    Jul

  • 01

    Aug

  • 06

    Aug

  • 21

    Aug

  • 21

    Aug

  • 13

    Nov

OVID

Ovid Therapeutics

$2.39

-0.19 (-7.36%)

04:55
07/17/19
07/17
04:55
07/17/19
04:55
Conference/Events
Ovid Therapeutics management to meet with JMP Securities »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

CLNE

Clean Energy

$2.75

-0.01 (-0.36%)

04:55
07/17/19
07/17
04:55
07/17/19
04:55
Conference/Events
Clean Energy management to meet with Craig-Hallum »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

  • 18

    Jul

  • 24

    Jul

  • 08

    Aug

VFF

Village Farms

$9.29

-0.125 (-1.33%)

04:55
07/17/19
07/17
04:55
07/17/19
04:55
Conference/Events
Village Farms management to meet with Roth Capital »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

CASY

Casey's General Stores

$160.35

0.98 (0.61%)

04:55
07/17/19
07/17
04:55
07/17/19
04:55
Conference/Events
Casey's General Stores management to meet with Jefferies »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

  • 18

    Jul

  • 13

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.